Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,690 matching trials from the live ClinicalTrials.gov search.
Filters: Scottsdale, Arizona Clear all
Completed Not applicable Interventional Results available

Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant

NCT03649074
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AKL-T01
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 14 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

Topical Agent for Treatment of Red Skin

NCT00279890
View directory record Official record
Conditions
Rosacea, Bilaterally Symmetric Red Skin on Cheeks
Interventions
Topical SR-01
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

NCT00257608
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, placebo, erlotinib HCl
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
177
States / cities
Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

NCT04770220
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Experimental: ALZ-801, Placebo Comparator: Placebo
Drug
Lead sponsor
Alzheon Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
55
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

NCT00003808
View directory record Official record
Conditions
Leukemia
Interventions
theophylline
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
68
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 29, 2026, 2:45 AM EDT
Active, not recruiting Phase 2 Interventional

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

NCT06369610
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Biospecimen Collection, Computed Tomography, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

NCT00235508
View directory record Official record
Conditions
Insomnia, Generalized Anxiety Disorder
Interventions
Eszopiclone (Lunesta)
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 29, 2026, 2:45 AM EDT
Terminated Phase 1 Interventional

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

NCT02837991
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms, Metastatic Renal Cell Carcinoma, Ovarian Clear Cell Carcinoma
Interventions
CDX-014
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 4 Interventional

A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation

NCT00216190
View directory record Official record
Conditions
Mechanically Ventilated and Intubated Subjects
Interventions
Dexmedetomidine HCL Injection, Midazolam Injection
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of Chemotherapy Treatment for Patients With Ovarian Cancer

NCT00428610
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
LY573636-sodium
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 29, 2026, 2:45 AM EDT
Active, not recruiting Phase 3 Interventional

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 63 Years
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
132
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 29, 2026, 2:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

NCT01989585
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Navitoclax, Pharmacological Study, Trametinib
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
49
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 29, 2026, 2:45 AM EDT
Withdrawn Phase 3 Interventional

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

NCT00576225
View directory record Official record
Conditions
NSCLC
Interventions
CT-2103/carboplatin, paclitaxel/carboplatin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
44
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Burbank, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 29, 2026, 2:45 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

NCT00445068
View directory record Official record
Conditions
Multiple Myeloma
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
24
States / cities
Scottsdale, Arizona • Berkeley, California • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

NCT05142774
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
102
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 29, 2026, 2:45 AM EDT
Active, not recruiting Phase 3 Interventional

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

NCT04365374
View directory record Official record
Conditions
Brain Metastases
Interventions
Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy
Device · Radiation
Lead sponsor
GT Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
37
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 29, 2026, 2:45 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

NCT05696717
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Interventions
Ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
26
States / cities
Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 29, 2026, 2:45 AM EDT
Terminated No phase listed Observational

Blood Biomarkers of Injury and Outcome in Traumatic Brain Injury

NCT01730443
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

NCT01088815
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine, nab-Paclitaxel, GDC-0449
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial

NCT06089135
View directory record Official record
Conditions
Treatment in Calcified Coronary Disease
Interventions
Intravascular Lithotripsy, Cutting Balloon
Device
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
21 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 29, 2026, 2:45 AM EDT
Recruiting Phase 4 Interventional

Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty

NCT06832878
View directory record Official record
Conditions
Arthroplasty
Interventions
Oral Tranexamic Acid
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 29, 2026, 2:45 AM EDT
Recruiting Phase 1 Interventional

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NCT07226843
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Interventions
LY4584180, Rituximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 2:45 AM EDT
Approved For Marketing No phase listed Expanded access

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

NCT02589717
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab [TECENTRIQ]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
40
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 29, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

NCT00564889
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cyclophosphamide, dexamethasone, lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 29, 2026, 2:45 AM EDT